1-8 of 8
Eugene Lifshits
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models

Luc Friboulet, Helen Zou, David P. Kodack, Lars D. Engstrom, Qiuhua Li, Melissa West, Ruth W. Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang, Sergei Timofeevski, Dac M. Dinh, Hieu Lam, Justine L. Lam, Shinji Yamazaki, Wenyue Hu, Bhushankumar Patel, Divya Bezwada, Sidra Mahmood, Eugene Lifshits, Timothy Affolter, Patrick B. Lappin, Hovhannes Gukasyan, Nathan Lee, Shibing Deng, Rakesh K. Jain, Ted W. Johnson, Alice T. Shaw, Valeria R. Fantin, Tod Smeal
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 130.
https://doi.org/10.1158/1538-7445.AM2015-130
Published: 01 August 2015
View article titled, Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
Journal Articles

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Aaron N. Hata, Alan Yeo, Anthony C. Faber, Eugene Lifshits, Zhao Chen, Katherine A. Cheng, Zandra Walton, Kristopher A. Sarosiek, Anthony Letai, Rebecca S. Heist, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2014) 74 (11): 3146–3156.
https://doi.org/10.1158/0008-5472.CAN-13-3728
Published: 29 May 2014
View article titled, Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
Open the PDF for Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers

Hiromichi Ebi, Ryan B. Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P. Ryan, Jeffrey A. Meyerhardt, Cyril Benes, Jeffrey Settleman, Lewis C. Cantley, Kwok-Kin Wong, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 956.
https://doi.org/10.1158/1538-7445.AM2011-956
Published: 15 April 2011
View article titled, Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers
Journal Articles

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

Jie Qi, Michele A. McTigue, Andrew Rogers, Eugene Lifshits, James G. Christensen, Pasi A. Jänne, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2011) 71 (3): 1081–1091.
https://doi.org/10.1158/0008-5472.CAN-10-1623
Published: 01 February 2011
View article titled, Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
Open the PDF for Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract #3874: MET amplification leads to resistance to the irreversible EGFR inhibitor PF00299804 through selection of a pre-existing MET amplified clone.

Kreshnik Zejnullahu, Young Chul Song, Eugene Lifshits, Luca Toschi, Andrew Rogers, Carly Murphy, Yun Xiao, Charles Lee, James Christensen, Jeffrey Engelman, Pasi Janne
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3874.
Published: 01 May 2009
View article titled, Abstract #3874: MET amplification leads to resistance to the irreversible EGFR inhibitor PF00299804 through selection of a pre-existing MET amplified clone.
Journal Articles

Abstract #1365: HGF induces transient and stable ligand-independent resistance in gefitinib-sensitive lung cancers

Alexa Turke, Youngchul Song, Neal Lindeman, Eugene Lifshits, Yun Xiao, Charles Lee, Pasi Janne, Jeffrey Engelman
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 1365.
Published: 01 May 2009
View article titled, Abstract #1365: HGF induces transient and stable ligand-independent resistance in gefitinib-sensitive lung cancers
Journal Articles

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, Eugene Lifshits, Andrea J. Gonzales, Takeshi Shimamura, Feng Zhao, Patrick W. Vincent, George N. Naumov, James E. Bradner, Irene W. Althaus, Leena Gandhi, Geoffrey I. Shapiro, James M. Nelson, John V. Heymach, Matthew Meyerson, Kwok-Kin Wong, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2007) 67 (24): 11924–11932.
https://doi.org/10.1158/0008-5472.CAN-07-1885
Published: 18 December 2007
View article titled, PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <em>EGFR</em> and <em>ERBB2</em> Mutations that Are Resistant to Gefitinib
Open the PDF for PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <em>EGFR</em> and <em>ERBB2</em> Mutations that Are Resistant to Gefitinib in another window
Includes: Supplementary data
Journal Articles

Stability of the angiogenic phenotype in human tumors: spontaneous tumor cell reversion to the non-angiogenic dormant state.

George Naumov, Katherine Novak, Eugene Lifshits, Elise Bender, David Cervi, David Zurakowski, Lars Akslen, Judah Folkman
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3055.
Published: 01 May 2007
View article titled, Stability of the angiogenic phenotype in human tumors: spontaneous tumor cell reversion to the non-angiogenic dormant state.